Congenital Adrenal Hyperplasia Market Report 2026

Congenital Adrenal Hyperplasia Market Overview

• Congenital Adrenal Hyperplasia market size has reached to $0.5 billion in 2025 • Expected to grow to $0.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Growing Demand For Gene Therapy Driving The Expansion Of The Market • Market Trend: Innovative Treatments In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Congenital Adrenal Hyperplasia Market?

Congenital adrenal hyperplasia refers to a group of inherited disorders affecting adrenal gland function due to enzyme deficiencies, primarily 21-hydroxylase. Congenital adrenal hyperplasia is managed through hormone replacement therapy to normalize cortisol and aldosterone levels, suppress excess androgen production, and address associated symptoms such as electrolyte imbalance and abnormal physical development. The main types of congenital adrenal hyperplasia (CAH) are classic congenital adrenal hyperplasia and non-classic congenital adrenal hyperplasia. Classic CAH is a genetic disorder primarily caused by 21-hydroxylase deficiency, leading to cortisol deficiency, excess androgens, and possible aldosterone loss. Diagnosis and treatment involve various healthcare settings, including hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

What Is The Congenital Adrenal Hyperplasia Market Growth Forecast?

The congenital adrenal hyperplasia market size is expected to see strong growth in the next few years. It will grow to $0.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to advancements in precision medicine approaches, expansion of genetic testing access, increasing healthcare expenditure, growth in specialty clinics, improved patient adherence through novel formulations. Major trends in the forecast period include expanded newborn screening programs, long-acting and modified-release steroid therapies, improved mineralocorticoid and androgen suppression regimens, rising adoption of multidisciplinary care models, increasing focus on lifelong disease management.

What Is The Driver Of The Congenital Adrenal Hyperplasia Market?

The rise in demand for gene therapy is expected to propel the growth of the congenital adrenal hyperplasia market going forward. Gene therapy refers to a medical technique that involves the modification or manipulation of an individual's genes to treat or prevent disease. The rise in demand for gene therapy is attributed to advancements in genetic research and biotechnology, which have enabled more precise and targeted treatments for genetic disorders, cancers, and other chronic diseases. The congenital adrenal hyperplasia (CAH) disorder, which is caused by mutations in genes responsible for adrenal hormone production, serves as a critical focus in gene therapy by offering opportunities for targeted genetic interventions to correct the underlying genetic defects and restore normal hormone function. For instance, in April 2024, according to the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, out of the 1,023 gene therapies in development for rare diseases, eight of the top 10 rare diseases were oncological. The second quarter of 2024 saw the initiation of 76 gene therapy trials, a 25% increase from the previous quarter. Therefore, the rise in demand for gene therapy is driving growth in the congenital adrenal hyperplasia industry.

Key Players In The Global Congenital Adrenal Hyperplasia Market

Major companies operating in the congenital adrenal hyperplasia market are Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., Crinetics Pharmaceuticals Inc.

Global Congenital Adrenal Hyperplasia Market Trends and Insights

Major companies operating in the congenital adrenal hyperplasia market are focusing on developing innovative treatments such as CRF1 receptor antagonists to regulate cortisol production and reduce adrenal androgen excess. CRF1 receptor antagonist refers to a drug that blocks the corticotropin-releasing factor 1 (CRF1) receptor to regulate the body's stress response and reduce excessive adrenal androgen production in conditions such as congenital adrenal hyperplasia. For instance, in December 2024, Neurocrine Biosciences, Inc., a US-based biopharmaceutical company, received FDA approval for crenessity (crinecerfont), the first new treatment for congenital adrenal hyperplasia (CAH) in 70 years. This oral medication acts as a selective antagonist of corticotropin-releasing factor type 1 receptors, helping to control excess adrenocorticotropic hormone (ACTH) and adrenal androgens while allowing for reduced glucocorticoid doses. Approval was based on data from the CAHtalyst Phase 3 studies, which showed significant efficacy in lowering androgen levels. Crenessity is expected to be available soon, marking a significant advancement in CAH management.

What Are Latest Mergers And Acquisitions In The Congenital Adrenal Hyperplasia Market?

In January 2023, Spruce Biosciences Inc., a US-based biotechnology company, partnered with Kaken Pharmaceutical Co., Ltd. to develop and commercialize tildacerfont for congenital adrenal hyperplasia (CAH) in Japan. With this partnership, Spruce Biosciences and Kaken aim to accelerate clinical development and regional commercialization by combining Spruce’s tildacerfont clinical program and regulatory data with Kaken’s Japan-market development, regulatory and commercial capabilities to improve patient access to a potential non-steroidal CAH therapy. Kaken Pharmaceutical Co. Ltd. is a Japan-based pharmaceutical company that specializes in the development, manufacturing and commercialization of prescription medicines.

What Defines the Congenital Adrenal Hyperplasia Market?

The congenital adrenal hyperplasia market consists of revenues earned by entities by providing services such as telemedicine and remote monitoring, diagnostic testing services, hormone replacement therapy (HRT) services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital adrenal hyperplasia market also includes sales of glucocorticoids, mineralocorticoids, and adrenal androgens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Congenital Adrenal Hyperplasia Market Report 2026?

The congenital adrenal hyperplasia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the congenital adrenal hyperplasia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.